Belgium’s UCB just dropped a $2 billion hammer on Gwinnett County. This isn't just another corporate expansion or a minor satellite office. It’s the largest capital investment in the history of the county, and it marks a massive shift for the drugmaker. While most people know them for allergy staples like Zyrtec, this new facility at Rowen signals a much deeper dive into the high-stakes world of biologics. They’re moving past simple pills and into the complex, lab-grown proteins that treat autoimmune and neurological diseases.
The numbers are staggering. We’re talking about a 460,000-square-foot facility. That’s roughly the size of eight football fields. It’s a 79-acre footprint within the Rowen innovation district, a 2,000-acre project that locals hope will eventually give North Carolina’s Research Triangle Park a run for its money. UCB already has its U.S. headquarters in Smyrna, so they aren't strangers to Georgia. But this move to Gwinnett is different. It’s about manufacturing independence and getting their most advanced drugs closer to the American patients who need them. You might also find this related article interesting: The Middle Power Myth and Why Mark Carney Is Chasing Ghosts in Asia.
The Strategy Behind the Spend
You don't just spend $2 billion on a whim. UCB is riding a massive wave of growth. In 2025, their revenue hit nearly $9 billion, up 26%. Their profit jumped even more—46% to $1.81 billion. Most of that is driven by their blockbuster drug Bimzelx, which treats psoriasis and inflammatory arthritis. When you have a hit like that, you don't want to rely solely on contract manufacturers. You build your own house.
This plant will be their first-ever U.S. pharmaceutical biologics manufacturing site. Historically, UCB relied on a mix of their own European plants and U.S.-based partners. By onshoring this production, they’re cutting down supply chain risks. If the last few years taught us anything, it’s that having your factory in a different time zone is a liability when demand spikes. As highlighted in detailed articles by Bloomberg, the effects are notable.
Why Gwinnett and Rowen
The choice of location was surgical. Rowen is positioned right between Georgia Tech in Atlanta and the University of Georgia in Athens. That’s a talent corridor. UCB needs people who can handle AI, robotics, and advanced automation, because this isn't going to be a 1950s assembly line. It’s a digital-first operation.
Gwinnett County didn't just win this on vibes, though. They put $174 million in incentives on the table. That includes property tax breaks and infrastructure upgrades. Add in state income tax credits and sales tax waivers on equipment, and the deal becomes hard to refuse. Critics often point to these "corporate giveaways," but the projected $5 billion total economic impact is the counter-argument the county is leaning on.
What This Means for Jobs
Let’s talk about the 330 permanent roles. These aren't entry-level warehouse jobs. We’re looking at an average annual salary of more than $72,000. In a region where the cost of living is rising but still manageable, those are solid, middle-class-plus career paths.
- Construction Surge: Before those 330 people ever clock in, over 1,000 construction workers will be on-site.
- High-Skilled Requirements: The roles will focus on biologics manufacturing, which requires specialized training in biotech and digital systems.
- Long-Term Security: Design and construction will take six to seven years. This is a long-term play, not a "here today, gone tomorrow" satellite office.
The Future of Biologics in the South
For a long time, if you wanted to work in big pharma manufacturing, you went to New Jersey or Massachusetts. That's changing. Georgia is aggressively trying to cultivate a life sciences ecosystem. The state already hosts more than 50 Belgian-invested companies. UCB’s move is a signal to other global players that the "Peach State" has the infrastructure and the talent to support the most complex manufacturing on the planet.
This investment also highlights UCB's pivot. They’re moving away from their mature neurology and allergy businesses—which they recently divested in some markets like China—to focus on "growth drivers." These are drugs like Fintepla and Rystiggo. These aren't easy to make. They require the kind of sophisticated biologics environment they’re building in Gwinnett.
Is the Investment Worth the Risk
There’s always a catch. Six to seven years is a long time in the pharmaceutical world. Patents expire. New competitors emerge. While Bimzelx is a titan right now, the market for autoimmune treatments is incredibly crowded. UCB is essentially betting $2 billion that their current pipeline will still be dominant by the time the ribbon is cut in 2032 or 2033.
However, the company’s "Be Bold" strategy seems to be paying off so far. They’ve secured 16 FDA approvals or expansions in the last few years alone. They aren't just sitting on old successes. They’re actively pushing into treatments for Parkinson’s and Alzheimer’s. If even one of those pipeline drugs hits the mark, they’ll need every square inch of that 460,000-square-foot plant.
If you’re looking to get into the biotech space in the Southeast, keep an eye on Gwinnett. This UCB project is just the anchor. Expect a wave of smaller lab spaces, logistics firms, and specialized contractors to cluster around Rowen over the next decade. The smart move is to start looking at the training programs at Georgia Tech and UGA now. The demand for these skills isn't going anywhere.
Check the Gwinnett County economic development portal for updates on infrastructure timelines if you’re a local business owner. If you’re a job seeker, start tailoring your resume for advanced manufacturing and digital-twin technology. The future of Georgia’s economy just got a lot more clinical.
